Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BetterLife Pharma ( (TSE:BETR) ) just unveiled an announcement.
BetterLife Pharma has engaged Shanghai-based YAFO Capital as its exclusive advisor to seek strategic partnerships for the development of its proprietary BETR-001 in the Greater China regions. This collaboration aims to leverage YAFO’s expertise and network to accelerate the development and strategic partnering opportunities for BETR-001, a non-hallucinogenic treatment for neurological disorders, in Asia.
Spark’s Take on TSE:BETR Stock
According to Spark, TipRanks’ AI Analyst, TSE:BETR is a Underperform.
BetterLife Pharma is currently in a precarious financial position with no revenue, substantial losses, and a high leverage risk due to negative equity. Technical indicators show a lack of momentum, and the valuation is unattractive due to negative earnings. The overall outlook is negative, reflecting significant financial instability.
To see Spark’s full report on TSE:BETR stock, click here.
More about BetterLife Pharma
BetterLife Pharma Inc. is an emerging biotechnology company focused on developing and commercializing BETR-001, a non-hallucinogenic derivative of LSD, for the treatment of various neurological disorders. The company is also exploring strategic alternatives for a drug candidate targeting viral infections.
Average Trading Volume: 125,300
Technical Sentiment Signal: Sell
Current Market Cap: C$9.87M
Find detailed analytics on BETR stock on TipRanks’ Stock Analysis page.